NICE hears appeals over dementia drugsBMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7560.165 (Published 20 July 2006) Cite this as: BMJ 2006;333:165
- Zosia Kmietowicz
The National Institute for Health and Clinical Excellence (NICE) last week heard five appeals over two days against its decision to restrict the use of drug treatments for Alzheimer's disease to patients with moderate stages of the condition.
In its original guidance, issued in January 2001, NICE recommended that the drugs donepezil, rivastigmine, and galantamine could be prescribed for people with mild and moderate stages of the disease, defined as having a score of 12 …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial